[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphadenectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphadenectomy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,56,87,113,138,169,199,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100584274","immediate-lymphatic-reconstruction-after-lymphadenectomy-in-melanoma-patients-a-parallel-cohort-pilot-study-100584274",false,"NCT06887205","Immediate Lymphatic Reconstruction After Lymphadenectomy in Melanoma Patients: a Parallel Cohort Pilot Study","Inclusion Criteria:\n\n1. Participants greater than or equal to 18 years of age.\n2. Participants willing to participate.\n3. Participants able to complete informed consent.\n4. Participants with a diagnosis of Melanoma undergoing ALND or ILND.\n\nExclusion Criteria:\n\n1. Participant staking anticoagulants within 7 days prior to surgery.\n2. Participants that are known to be pregnant at the time of surgery.\n3. Participants with BMI greater than 50.0","ALL","18 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"NA","To learn if LBP can help to prevent lymphedema when it is performed at the time of surgery rather than after a patient has already developed the disease.",[25,26],"Lymphatic Reconstruction","Lymphadenectomy","RECRUITING","2026-06-16",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":31},"2026-06-10",{"date":35,"type":19},"2028-09-01",{"name":37,"class":38},"M.D. Anderson Cancer Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":47,"phases":4,"briefSummary":23,"conditions":48,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":39},"100515546","prophylactic-lymphovenous-bypass-procedure-following-inguinal-lymphadenectomy-or-pelvic-lymphadenectomy-a-prospective-observational-study-100515546","NCT05992909","Prophylactic Lymphovenous Bypass Procedure Following Inguinal Lymphadenectomy or Pelvic Lymphadenectomy: A Prospective Observational Study","Eligibility Criteria:\n\n1. Patients greater than or equal to 18 years of age.\n2. Patients willing to participate.\n3. Patients able to complete informed consent.\n4. Patients undergoing ILND and\u002For PLND.\n\nExclusion Criteria:\n\n1. Patients taking anticoagulants within 7 days prior to surgery.\n2. Patients that are known to be pregnant at the time of surgery.\n3. Patients are available for follow-up less than 18 months or do not undergo measurements within the scheduled period.\n4. Patients with BMI greater than 50.0.",{"count":18,"type":19},"OBSERVATIONAL",[26],"2026-06-12",{"date":28,"type":31},{"date":52,"type":31},"2023-08-02",{"date":54,"type":19},"2027-08-01",{"name":37,"class":38},{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":64,"minAge":16,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":20,"phases":67,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100585301","sentinel-node-mapping-versus-comprehensive-lymphadenectomy-in-p53-mutated-endometrial-cancer-a-non-inferiority-randomized-trial-100585301","NCT06900582","SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53-Mutated Endometrial Cancer: A Non-Inferiority Randomized Trial","Comparing SENTInel Node Mapping to Comprehensive Lymphadenectomy in p53-Mutated EndoMETRial Cancer: a Prospective, Open-label, Controlled, Randomized, Non-inferiority, De-escalation Trial","SENTIMETREP53","Inclusion Criteria:\n\n1 . ≥ 18 years old 2. High-risk endometrial cancer, as defined by the ESGO-ESTRO 20211 histological and molecular classification, with p53 mutation confirmed on endometrial biopsy or curettage in the two months before the surgery 3. Magnetic Resonance Imaging (MRI) confirmed FIGO 2023 stage I and II endometrial cancer, i.e., confined to the uterine corpus, ovary and the cervical stroma.\n\n4\\. Participant with a scheduled surgical intervention (total hysterectomy and bilateral salpingo-oophorectomy, with omentectomy in the case of serous, carcinosarcoma and undifferenciated type EC) 5. Eligible for comprehensive lymphadenectomy by laparoscopy 6. Participant with a negative Positron Emission Tomography scan (PET-CT scan) for lymph node involvement in the two months before the intervention 7. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1 8. Participant able to provide written informed consent\n\nExclusion Criteria:\n\n1. Recurrent EC\n2. Previous chemo-, radio, or endocrine therapy for EC\n3. Any contra-indication to lymphadenectomy and\u002For chemotherapy\n4. Any contraindication to laparoscopy\n5. Any criteria, based on the investigator's judgment, that would contraindicate the surgical procedure (e.g., but not limited to, anesthetic risk, bleeding, significant comorbidities)\n6. Any known disorder or circumstances making participation in trial and follow-up questionable\n7. Patients with other malignancies for whom the disease(s) and\u002For associated treatment(s) might have an impact on the patient's cancer prognosis\n8. Known HIV-infection or AIDS\n9. Simultaneous participation in another interventional clinical trial\n10. Within the exclusion period following participation in another interventional clinical trial\n11. Patients with difficulties in reading or understanding French, or an inability to understand the delivered information\n12. Patients in emergency medical situations\n13. Patient under guardianship or limited guardianship","FEMALE",{"count":66,"type":19},374,[22],"This study evaluates surgical strategies for treating patients with FIGO 2023 stage I and II high-risk endometrial cancer (EC) exhibiting p53 mutations. The trial aims to assess whether a less invasive sentinel lymph node (SLN) mapping approach provides non-inferior oncological outcomes compared to the current standard of systematic pelvic and para-aortic lymphadenectomy (PL+PALND). By minimizing surgical morbidity, this study seeks to determine if SLN mapping can safely replace comprehensive lymphadenectomy without compromising disease-free survival (DFS). Eligible patients will be randomized to undergo either sentinel lymph node mapping or complete lymphadenectomy, followed by standard hysterectomy and bilateral salpingo-oophorectomy. The primary outcome is DFS at 36 months, with secondary outcomes including overall survival, disease-specific survival, perioperative complications, and quality of life.",[26,70,71,72],"Endometrial Cancer","Gene, p53","Sentinel Lymph Node Biopsy (SLNB)",[74,75,26,76],"Endometrial cancer","Sentinel lymph node biopsy","p53 mutation","NOT_YET_RECRUITING","2026-02-13",{"date":80,"type":31},"2026-02-17",{"date":82,"type":19},"2026-06",{"date":84,"type":19},"2031-10",{"name":86,"class":38},"University Hospital, Strasbourg, France",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":20,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":39},"100616255","phase-3-the-value-of-indocyanine-green-guided-near-infrared-fluorescence-technology-in-tracing-sentinel-lymph-nodes-during-esophagectomy-100616255","NCT07303231","The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy","The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age and gender: 18-75 years old, male and female unlimited;\n2. Preoperative biopsy was pathologically diagnosed as esophageal squamous cell carcinoma;\n3. Preoperative combination with neoadjuvant chemoradiotherapy;\n4. Surgical resection of esophageal carcinoma under endoscopic selection and intraoperative anastomosis;\n5. Heart, lung, liver and kidney functions can tolerate operation;\n6. Patients and their family members can understand and are willing to participate in this clinical study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Allergic to ICG or iodine;\n2. Patients with a history of chest surgery or thoracic lymph node dissection;\n3. Patients needing emergency surgery;\n4. Patients whose tumors involve neighboring organs and need to be removed by combining organs;\n5. Patients with tumor recurrence or distant metastasis;\n6. Patients who had participated in or were participating in other clinical trials within the previous 4 weeks were included;\n7. A history of serious mental illness;\n8. Pregnant or lactating women;\n9. Patients with other conditions considered by the researcher should not participate in the study.","75 Years",{"count":96,"type":19},144,[98],"PHASE3","Sentinel lymph nodes, as the primary site of tumor metastasis, play a pivotal role in assessing patient prognosis and planning subsequent treatment strategies. The investigators plan to conduct a multicenter, prospective cohort study to evaluate the effectiveness of indocyanine green (ICG)-guided near-infrared imaging in tracing sentinel lymph node during esophageal squamous cell carcinoma (ESCC) surgery, compared with the gold standard of complete lymph node dissection (CLND), in detecting metastatic disease. This study aims to address the following core questions:\n\n1. In ESCC patients undergoing surgery, can sentinel lymph node biopsy reduce unnecessary lymph node dissection?\n2. In ESCC patients undergoing surgery, can reducing lymph node dissection decrease postoperative complications such as chylothorax and weakened immunity? During the study, ICG will be injected around the tumor under intraoperative gastroscopy guidance, followed by tracking of fluorescent lymph nodes using a thoracoscopic near-infrared camera. Professional thoracic surgeons will group and mark these lymph nodes for intraoperative frozen pathology. Subsequent CLND and routine postoperative pathology will be performed. This study will collect patients' clinical information, ICG imaging results, pathological examination results, and other data for statistical analysis to assess the sensitivity and negative predictive value (NPV) of the ICG imaging system. If the study results support the effectiveness of the ICG imaging system, it has the potential to become an important tool for sentinel lymph node localization and biopsy in future ESCC surgeries, helping to reduce unnecessary lymph node resection and improve surgical efficiency and safety.\n\nParticipants will:\n\n1. Undergo minimally invasive ESCC surgery within 2 weeks of enrollment, including the 14th day.\n2. Receive ICG injection around the tumor under intraoperative gastroscopy guidance during surgery.\n3. Have perioperative, postoperative pathology, and complication information recorded.\n4. Undergo standardized follow-up after surgery.",[101,102,26,103],"Esophageal Cancer","Sentinel Lymph Node","Indocyanine Green","2025-12-11",{"date":106,"type":31},"2025-12-24",{"date":108,"type":19},"2026-01-01",{"date":110,"type":19},"2028-02-01",{"name":112,"class":38},"Fujian Medical University Union Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":121,"enrollmentInfo":122,"targetDuration":124,"studyType":47,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":39},"100541380","right-colectomy-for-colon-cancer-database-rcc-surgical-technique-route-of-access-and-quality-of-the-specimen-100541380","NCT06329102","Right Colectomy for Colon Cancer Database (RCC). Surgical Technique, Route of Access and Quality of the Specimen","Right Colectomy for Colon Cancer Database","RCC","Inclusion Criteria:\n\n* Patients with malignant tumor of the right colon at CT and\u002For colonoscopy.\n* Confirmed adenocarcinoma\n* Patients medically cleared by anesthesiologist for general anesthesia and oncological radical resection\n* Informed consent\n\nExclusion Criteria:\n\n* Patients under 18 years\n* Patients with recurrent cancer after previous surgery\n* Patients with ongoing treatment due to other cancer","99 Years",{"count":123,"type":19},1000,"5 Years","Aim of the project is to surveil results after extended lymphadenectomy for right sided colon resection for cancer with different operative techniques. Patients operated for right sided colon cancer will be involved. There are different operative methods used in terms of extend of lymphadenectomy and access (open, laparoscopic and robotic assisted) that are already implemented. The Norwegian standard operation contains less extended lymph node dissection. Patients operated by the standard method will serve as control group. Choice of access and extend of lymph node dissection in Norway is dependant on the surgeon and hospital. At Haukeland University Hospital extend and access of surgery are determined by a multidisciplinary team meeting. More radical surgery might result in more complications and the benefit for the patients in terms of oncological result and survival is uncertain. At Haukeland University Hospital, extended lymphadenectomy has been mostly performed by open surgery. During the study phase we will introduce extended lymphadenectomy by laparoscopy and robotassisted surgery. Hypothesis is that more radical surgery performed by minimal invasive surgery will result in equal or better oncological results, and less complications, shorter hospital stay and better quality of life. As method we choose a prospective observational study. All eligible patients with adenocarcinoma of the right colon without another ongoing oncological treatment for other cancers will be included. Patientdata will be prospectively registered in a web-based database. Aim of the study will be to define the optimal extend of lymphadenectomy to achieve the best oncological result. In addition, we will analyse the results dependent on the surgical access (open, laparoscopic or robotic). The assumed difference between the operative methods is small. Therefore, the study is designed and approved as a multicenter registration in order to achieve the necessary statistical power.",[127,128,26],"Right Sided Colon Cancer","Right Colectomy","2025-09-09",{"date":131,"type":31},"2025-09-15",{"date":133,"type":31},"2021-01-01",{"date":135,"type":19},"2030-09-01",{"name":137,"class":38},"Haukeland University Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":20,"phases":149,"briefSummary":150,"conditions":151,"keywords":156,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":39},"100584672","application-of-indocyanine-green-tracer-in-d2-lymphadenectomy-of-locally-advanced-gastric-cancer-100584672","NCT06892392","Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer","Aplicación Del ICG En La Linfadenectomía D2 Laparoscópica Del Cáncer Gástrico Localmente Avanzado: Ensayo Clínico Aleatorizado Multicéntrico.","Gastri-ICG","Inclusion Criteria:\n\n* T2-T4a, N+, M0 on preoperative study\n* PS 0-1\n* ASA I-III\n* Laparoscopic surgery\n\nExclusion Criteria:\n\n* \\- Previous gastric abdominal surgery\n* DSE\n* Cognitive impairment\n* Allergic to iodine\n* Synchronous neoplasm\n* Stroke in the last 6 months\n* Angina or AMI in the last 6 months\n* Plastic lymphitis\n* Open surgery","85 Years",{"count":148,"type":19},102,[22],"Gastric cancer is a frequent neoplasm in the world, presenting more than one million new cases and around 768,000 deaths in the data registered in 2020. Among the therapeutic options for gastric cancer, surgery is an essential pillar for its treatment. Gastric cancer surgery consists of gastric resection with negative margins and radical lymphadenectomy in patients without distant metastases. It has been demonstrated over the years that radical lymphadenectomy in gastric cancer allows for adequate staging and improved long-term survival.\n\nIn order to perform a correct staging using the TNM system, it is necessary to resect at least 15 lymph nodes in the radical lymphadenectomy. For radical lymphadenectomy staging, the Japanese Gastric Cancer Association defined and subdivided nodal stations. Three types of lymphadenectomy are described according to oncologic gastric resections (D1, D1+ and D2), with D2 lymphadenectomy being the standard of treatment for locally advanced gastric tumors. Performing an insufficient or inadequate lymphadenectomy has been shown to negatively impact survival after gastrectomy in such a cohort.\n\nThe development of technology based on fluorescence guided by indocyanine green could improve the technique and results of D2 lymphadenectomy in patients with gastric cancer. There is evidence that the application of ICG in D2 lymphadenectomy increases the number of resected nodes, however, studies of higher scientific quality (randomized clinical trials) are needed. Furthermore, most studies in this field have focused on Eastern countries (Japan, Korea and China), where the percentage of early tumors and chemotherapy treatment is different from Western centers.\n\nTherefore, we propose a multicenter randomized clinical trial aimed at evaluating whether the application of ICG-guided fluorescence-based technology in D2 lymphadenectomy of locally advanced gastric cancer increases the number of resected nodes, improves the oncologic quality of the lymphadenectomy, and thus may increase overall survival and disease-free survival at 2 and 5 years postoperatively.",[152,153,154,26,155],"GASTRIC CANCER","Indocyanine Green (ICG)","Lymph Node Excision","Laparoscopic Gastrectomy",[157,158,159],"Multicenter randomized 1:1 clinical trial","indocyanine green","Laparoscopic gastrectomy with D2 lymphadenectomy","2025-03-18",{"date":162,"type":31},"2025-03-24",{"date":164,"type":19},"2026-03-01",{"date":166,"type":19},"2032-12",{"name":168,"class":38},"Hospital of Navarra",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":64,"minAge":16,"maxAge":146,"enrollmentInfo":176,"targetDuration":4,"studyType":20,"phases":178,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":39},"100583021","comparison-of-transvaginal-paracervical-and-transperitoneal-approaches-in-lymphadenectomy-during-v-notes-surgery-for-patients-diagnosed-with-endometrial-cancer-100583021","NCT06870903","Comparison of Transvaginal Paracervical and Transperitoneal Approaches in Lymphadenectomy During v-NOTES Surgery for Patients Diagnosed With Endometrial Cancer","ENDONOTE","Patient Selection and Data Collection This study will be implemented in a single institution, Diyarbakır Gazi Yaşargil Training and Research Hospital, which functions as a tertiary cancer treatment facility.\n\nBetween March 2025 and December 2025, patients with newly diagnosed clinical early stage (FIGO 2023 stages 1 and 2) endometrial cancer who will be treated with laparoscopic surgical staging with SLN mapping at our institution will be randomized into groups. The research procedure has been approved by the ethics committee\u002Finstitutional review board of Diyarbakır Gazi Yaşargil Training and Research Hospital and informed consent signed by the patient will be included in each table reviewed.\n\nEligible participants will be required to give informed consent to participate in the study.\n\nInclusion criteria will include\n\n* Participants whose endometrial biopsy resulted in endometrial cancer and whose disease will be detected limited to the uterus using imaging modalities (computed tomography \\[CT\\], magnetic resonance imaging or Fluorine-18 fluorodeoxyglucose positron emission tomography\u002FCT)\n* Absence of synchronous malignancies.\n* No neoadjuvant treatment before surgical intervention.\n\nExclusion criteria will include:\n\n* Contraindications to using methylene blue dye or contraindications to the vNOTES procedure.\n* Patients who have had previous malignancy surgery.\n* Severe, deeply penetrating endometriosis or enlarged uterus that may require forced vaginal extraction\n* Receiving neodajuvant therapy",{"count":177,"type":19},52,[22],"The aim of this study is to compare two types of lymphadenectomy (transperitoneal vs. paracervical) during the lymphadenectomy phase of endometrial cancer staging surgery performed using V-NOTES, a new and advanced technique. This study seeks to optimize the V-NOTES technique for endometrial cancer staging. This randomized, prospective, controlled study will include patients diagnosed with endometrial cancer via histology, following physical examination and imaging, and who are electively scheduled for the V-NOTES endometrial cancer staging procedure. Patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group. The parameters related with surgical and functional outcomes will be compared in both groups.",[70,26,181,182,183],"Sentinel Lymph Node Biopsy","Minimally Invasive Surgical Procedures","Natural Orifice Transluminal Endoscopic Surgery",[185,186,187,188,189,190],"endometrial cancer","V-NOTES","lymphadenectomy","sentinel lymph node","transperitoneal","extraperitoneal","2025-03-17",{"date":193,"type":31},"2025-03-20",{"date":195,"type":31},"2025-03-15",{"date":164,"type":19},{"name":198,"class":38},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":47,"phases":4,"briefSummary":209,"conditions":210,"keywords":220,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":232},"100551962","evaluation-of-intra-operative-photographs-for-the-assessment-of-a-proper-lymphadenectomy-in-minimally-invasive-gastrectomies-for-gastric-cancer-photonodes-100551962","NCT06466902","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastric Cancer Surgery (PhotoNodes)","PhotoNodes","Inclusion Criteria:\n\n* All patients undergoing minimally invasive curative-intent surgery for gastric adenocarcinoma with D2 lymphadenectomy\n* Patients undergoing upfront surgery or treated with a neoadjuvant\u002Fperioperative chemotherapy\n* Total or Subtotal Gastrectomy\n* Laparoscopic or Robotic approach\n\nExclusion Criteria:\n\n* Age less than 18 year old\n* Esophago-gastric junction cancer Siewert type I, II or III\n* Metastatic disease\n* Lymphadenectomy less than D2\n* Open surgery\n* Conversion to open surgery\n* Palliative gastrectomy\n* R1 or R2 resection\n* Multivisceral resection except for cholecystectomy\n* Surgical procedures other than subtotal or total gastrectomy\n* A single node station rated as unevaluable by more than one reviewer",{"count":208,"type":19},326,"Even after the wide introduction of chemo\u002Fradiotherapy in the treatment algorithm, adequate surgery remains the cornerstone of gastric cancer treatment with curative intent. A proper D2 lymphadenectomy is associated with improved cancer specific survival as confirmed in Western countries by fifteen-year follow-up results of Dutch and Italian randomized trials.\n\nIn clinical practice, the total number of harvested lymph nodes is often considered as a surrogate marker for adequate D2 lymphadenectomy; nonetheless, the number of retrieved nodes does not necessarily correlate with residual nodes, which intuitively could represent a more reliable marker of surgical adequacy. The availability of an efficient tool for evaluating the absence of residual nodes in the operative field at the end of node dissection could better correlate with survival outcomes.\n\nThe goal of this multicentric observational prospective study is to test the reliability of a new score (PhotoNodes Score) created to rate the quality of the lymphadenectomy performed during minimally invasive gastrectomy for gastric cancer. The score is assigned by assessing the absence of residual nodes at the end of node dissection on a set of laparoscopic\u002Frobotic high quality intraoperative images collected from each patient undergoing a minimally invasive gastrectomy with D2 node dissection.\n\nIdeally, this tool could be a new indicator of the quality of D2 dissection and could assume a prognostic role in the treatment of gastric cancer.",[211,212,26,213,214,215,216,217,218,219],"Gastric Cancer","Gastric Adenocarcinoma","Minimally Invasive Surgery","Gastrectomy for Gastric Cancer","Laparoscopic Surgery","Robotic Surgery","Survival Outcomes","Survival Analysis","Quality Of Care",[221,222],"D2 Lymphadenectomy quality assessment","Minimally invasive gastric cancer oncologic surgery","2024-07-03",{"date":225,"type":31},"2024-07-05",{"date":227,"type":31},"2022-12-22",{"date":229,"type":19},"2027-12",{"name":231,"class":38},"Azienda Ospedaliero-Universitaria di Parma",8,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":64,"minAge":16,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":20,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":39},"100417062","lymphadenectomy-in-early-ovarian-cancer-100417062","NCT04710797","Lymphadenectomy in Early Ovarian Cancer","A Prospective Randomized Multicentre Trial for Lymphadenectomy in Early-stage Ovarian Cancer","LOVE","Inclusion Criteria:\n\n1. Women aged 18 years to 70 years.\n2. Primary diagnosis of epithelial ovarian cancer FIGO stage IA-IIA ( recevive no prior treatment or receive incomplete initial surgery)，with indications of adjuvant chemotherapy：①High-grade serous carcinoma; ②Grade 3 endometrioid carcinoma; ③Clear cell carcinoma; ④Grade 2 endometrioid carcinoma with capsule ruptured or pelvic tissues extension ⑤Low-grade serous carcinoma、Grade 1 endometrioid carcinoma and Mucinous carcinoma of the ovary with pelvic tissues extension.\n3. Patients who have given their signed and written informed consent.\n4. Good performance status (ECOG 0\u002F1).\n\nExclusion Criteria:\n\n1. Non epithelial ovarian malignancies and borderline tumors.\n2. Suspicious lymph nodes at preoperative radiological evaluation.\n3. Intraoperative clinically suspicious lymph nodes (bulky nodes).\n4. Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1\u002F2, non melanoma skin cancer, breast cancer T1 N0 M0 G1\u002F2) or with any signs of relapse or activity.\n5. Prior chemotherapy for ovarian cancer or abdominal\u002Fpelvic radiotherapy.\n6. Diseases of the lymph system (including lymph edema of unknown origin).\n7. Prior retroperitoneal lymph node dissection (systematic or sampling).\n8. Any other concurrent medical conditions contraindicating surgery.\n9. Pregnancy.\n10. Any reasons interfering with giving of informed consent , abiding by protocol, or regular follow-up.","70 Years",{"count":243,"type":19},656,[22],"To assess the impact of comprehensive staging surgery with no lymphadenectomy on survival and quality of life in patients with early-stage ovarian cancer.",[247,26],"Ovarian Cancer","2021-01-13",{"date":250,"type":31},"2021-01-15",{"date":252,"type":19},"2021-01-31",{"date":254,"type":19},"2028-12-31",{"name":256,"class":38},"Sun Yat-sen University"]